Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Pfizer    PFE

PFIZER (PFE)
Mes dernières consult.
Most popular
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets
Latest Tweets
10/19Pfizer, Inc. to Post Q4 2017 Earnings of $0.57 Per Share, SunTrust Banks Fore.. 
10/19Pfizer Quietly Takes Passive Stake in This Boston Pharma  
10/19Get ready for precision and invasive pharmaceutical ads $PFE  
10/19Dow Jones Analysis Video - $DJIA $DIA $SDOW $XOM $GE $GS $MRK $PFE $BMY $VZ .. 
10/19EDGE board approves incentives to entice Amazon warehouse, Pfizer jobs
3
10/18General Electric, Johnson & Johnson and Pfizer are accused of funding a S..
2
10/18BRIEF-Pfizer reports 5.4 pct passive stake in Rhythm Pharmaceuticals - ??SEC .. 
10/18Which lung cancer drug is better, Pfizer's or Ignyta's? The trial to find out..
3
10/18Reckitt is encouraging speculation it wants Pfizer's non-prescription drugs: .. 
10/18I just came across this $AZN slide from a couple of years back $RXDX $LOXO $S..
1
10/18U.S. veterans sue Pfizer, J&J and three others for funding terror in Iraq.. 
10/18I agree with . A single progression potentially wipes out entrectinib's acros..
1
10/18Pfizer's Advil may be just the thing for sickly Reckitt
1
10/18Reckitt makeover clears way for Pfizer bid
1
10/18  
10/18Pfizer, NEA back Cydan II’s plans to launch a fresh slate of biotech startups.. 
10/18Ignyta NSCLC durability data set stage for Pfizer fight  
10/18Ignyta lung cancer data for entrectinib sets up hopes of filing, Pfizer rival..
3
10/18Pfizer's Advil may be just the thing for sickly Reckitt
8
10/18Looks like the entrectinib median DOR in Ros1+ NSCLC (28.6mth, vs historic 18..
14
10/18Tiny Ignyta's #LungCancer Drug Bested Pfizer's. Probably. Will We Ever Know F..
1
10/18Fulton Breakefield Broenniman LLC Has $10.49 Million Stake in Pfizer, Inc. $P.. 
10/18Janney Montgomery Scott LLC Has $60.53 Million Holdings in Pfizer, Inc. $PFE .. 
10/18Tiny Ignyta's Lung Cancer Drug Bested Pfizer's. Probably. Will We Ever Know F..
26
10/18Dow Jones Analysis Video - $DJIA $DIA $SDOW $XOM $GE $GS $MRK $PFE $BMY $VZ .. 
10/17Excited 2b representing @dnanexus at @pfizer #EX2017 innovation conference+wo.. 
10/17[SPONSORED] As the U.S. healthcare system evolves, patients need guidance. Pf..
6
10/17Get ready for precision and invasive pharmaceutical ads $PFE  
10/17Pfizer, NEA back Cydan's plans to launch a fresh slate of biotech startups fo..
2
10/17Pfizer, NEA back Cydan II’s plans to launch a fresh slate of biotech startups..
1
10/17@ SMIpharm: RT PharmaMKTnet: Learn how to build integrated, impactful social .. 
10/17  
10/17Bowling Portfolio Management LLC Raises Stake in Pfizer, Inc. $PFE  
10/17Learn how to build integrated, impactful social media strategies with Pfizer ..
2
10/17Pfizer and Merck are dropping OTC brands just as consumer-health shows signs ..
54
10/17Traders Buy Shares of Pfizer, Inc. $PFE on Weakness  
10/17Dow Jones Analysis Video - $DJIA $DIA $SDOW $XOM $GE $GS $MRK $PFE $BMY $VZ .. 
10/16And Neel Lilani will interview Elaine Jones of Pfizer Venture Investments on .. 
10/16Peores del Dow Jones: Walmart, Pfizer, American Express...
1
10/16Will more drug makers file antitrust lawsuits against rivals? Mike Carrier ex.. 
10/16What is the real reason Pfizer wants out of consumer health? -- Heard on the ..
8
10/16After getting skunked by rivals, Pfizer touts ‘breakthrough’ cancer drug lorl.. 
10/16$PFE aims "breakthrough" ALK inhibitor lorlatinib at NSCLC, looks to regulato..
3
10/16
1
10/16  
10/16  
10/16Pfizer's lorlatinib shows treatment effect in mid-stage lung cancer study  
10/16Pfizer given $38.00 PT by Jefferies Group LLC. neutral rating.  
10/16Pharmalot.. Pharmalittle.. Good Morning.. headlines & coffee are served.... 
10/16After getting skunked by rivals, Pfizer touts ‘breakthrough’ cancer drug lorl..
1
More tweets
Qtime:870
Financials ($)
Sales 2017 52 676 M
EBIT 2017 19 837 M
Net income 2017 12 051 M
Debt 2017 24 101 M
Yield 2017 3,58%
P/E ratio 2017 19,26
P/E ratio 2018 16,94
EV / Sales 2017 4,51x
EV / Sales 2018 4,31x
Capitalization 213 B
Chart PFIZER
Duration : Period :
Pfizer Technical Analysis Chart | PFE | US7170811035 | 4-Traders
Technical analysis trends PFIZER
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 38,2 $
Spread / Average Target 6,6%
EPS Revisions
Managers
NameTitle
Ian C. Read Chairman & Chief Executive Officer
Frank A. D'Amelio Chief Financial Officer & EVP-Business Operations
Freda C. Lewis-Hall Chief Medical Officer & Executive Vice President
W. Don Cornwell Independent Director
Dennis Arthur Ausiello Lead Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
PFIZER10.31%213 372
JOHNSON & JOHNSON22.11%377 585
NOVARTIS13.50%226 453
ROCHE HOLDING LTD.5.55%215 760
MERCK AND COMPANY7.88%173 214
AMGEN27.41%135 924